TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced additional results from its Phase 1a dose-escalation trial evaluating TTX-MC138, an investigational microRNA-10b inhibitor for advanced cancer. The study met its primary safety endpoint with no dose-limiting toxicities observed across 16 patients who received a total of 86 doses. The company reported durable disease stabilization in multiple patients, including three participants who remain on treatment after 14, 16 and 21 cycles, supporting advancement of TTX-MC138 into Phase 2a clinical development.
Among 14 evaluable patients, nine (64%) achieved stable disease lasting six months based on RECIST criteria. TransCode also reported pharmacokinetic data demonstrating drug bioavailability consistent with preclinical findings and highlighted a metastatic thyroid cancer patient who experienced a significant decline in thyroglobulin levels and has maintained stable disease for 12 months. The company said the results support selection of a recommended Phase 2a dose of 4.8 mg/kg and provide a rationale for continued clinical development in patients with limited treatment options.
For business leaders, the implications are significant. TTX-MC138 targets metastatic tumors that overexpress microRNA-10b, a unique biomarker of metastasis. If successful in later-stage trials, this could represent a new therapeutic approach for patients with advanced cancers who currently have few options. The positive safety profile and evidence of durable disease stabilization suggest the drug may offer a tolerable and effective treatment, potentially reshaping standard of care in oncology. TransCode's progress also highlights the growing role of RNA therapeutics in cancer treatment, an area that has garnered increasing investment and attention.
The company is a clinical-stage firm pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. In addition to TTX-MC138, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. For investors and industry watchers, the Phase 1a results de-risk the program and support continued development. The full press release is available at https://ibn.fm/4WzoX. For the latest news and updates relating to RNAZ, visit the company’s newsroom at https://ibn.fm/RNAZ.
